The Long Run with Luke Timmerman
MurmurCast publishes AI-generated summaries of The Long Run with Luke Timmerman’s Podcast episodes — 5 summarized so far, covering Maze Therapeutics, APOL1 kidney disease, Regulatory landscape in drug development, Pulmonary fibrosis treatment and unmet patient needs, Inhalable drug reformulation strategy, Device-drug combination patents and regulatory barriers to entry. Each summary distills the key insights, topics, and takeaways so you can decide what’s worth your time before pressing play.
Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases
Jason Coloma, CEO of Maze Therapeutics, discusses the company's focus on developing genetic medicines for kidney diseases, rooted in human genetics and aimed at tackling complex diseases. The conversation covers Maze's journey from initial funding challenges to pursuing innovative drug development strategies and navigating regulatory hurdles.
Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases
Lynn Baranowski, CEO of Avalon Pharma, discusses her journey from diplomacy to biotech entrepreneurship and the company's strategy of reformulating existing pulmonary fibrosis drugs as inhalable treatments to improve patient tolerability and efficacy. She explains how delivering approved oral drugs directly to the lungs via nebulizer allows for dramatically reduced doses while maintaining or improving therapeutic benefit.
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
Heather Turner, CEO of LB Pharmaceuticals, discusses her unconventional path from corporate attorney to biotech CEO, leading the development of LB102, a methylated derivative of amisulpride for treating schizophrenia and other neuropsychiatric disorders. She successfully navigated a challenging IPO during a biotech financing freeze and is now advancing the compound through late-stage clinical trials with a focus on improving patient adherence and reducing side effects.
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
Troy Wilson, CEO of Cura Oncology, discusses his journey from mediocre student to serial biotech entrepreneur, the development of Ziftimenib (a Menin inhibitor approved for AML), and the company's strategy of combining precision cancer drugs like farnesyl transferase inhibitors with emerging RAS inhibitors to overcome treatment resistance.
Ep201: Jeremy Levin on Biotech in the Balance
Jeremy Levin, founder of Ovid Therapeutics and author of 'Biotech in the Balance,' discusses the systemic decline in public trust toward the biotechnology industry, tracing it from the Shkreli scandal through COVID-19 and into the current era of hostile policy. He argues the industry must recognize itself as strategically vital and offers ten commitments—including transparency, patient-centricity, and long-term capital formation—to rebuild its standing with the public and policymakers.